Added to YB: 2025-06-30
Pitch date: 2025-06-27
VYNE [bullish]
VYNE Therapeutics Inc.
-74.45%
current return
Author Info
Biotenic is a freelance L/S biotech investment analyst sharing investment theses. Sign up for the newsletter.
Company Info
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions.
Market Cap
$12.5M
Pitch Price
$1.47
Price Target
3.00 (+699%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-0.47
EV/Sales
-38.62
Sector
Pharmaceuticals
Category
growth
VYNE Therapeutics -- Ph2b vitiligo data due mid year
VYNE: Topical BET inhibitor for vitiligo with Ph2b readout in Aug. Expect positive vs placebo but may not beat Opzelura's 45-50% FVASI50. $75M mcap ($50M cash). Advantages: once-daily, no black box warning vs JAK. Bull case: $200M+ peak sales potential, $3 PT (85% upside). Risk: dose-related safety issues at 3%.
Read full article (5 min)